Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IDRCB | Other Identifier | 2025-A02589-40 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Better identification of ADHD in vulnerable people with SUD is essential to improving their care. This project aims to provide appropriate support for this at-risk population.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Workshops | Experimental | Workshops with a small group of patients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Workshop | Other | Assess the 5 workshops, co-constructed by the scientific committee and thanks to feedback from the qualitative study |
|
| Measure | Description | Time Frame |
|---|---|---|
| 80% of patients participated in the workshops | The primary outcome measure is the acceptability of the program to participants in the pilot workshops, gathered through:
| From enrollment to the end of wordshop at 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| SF-12 quality of life | The secondary outcome measure will be measured by the SF-12 quality of life, before and after the 5 workshops. The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. | From enrollment to the end of wordshop at 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marie BARAIS, MD | Contact | +332 98 01 64 02 | marie.barais@gmail.com | |
| Tiphaine MENEZ | Contact | +33230338460 | tiphaine.menez@chu-brest.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Brest | Brest | 29200 | France |
|
All collected data that underlie results in a publication
Data will be available after the publication of result and ending fifteen years following the last visit of the last patient.
Data access requests will be reviewed by the internal committee of BrestUH. Requestors will be required to sign and complete a data access agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| D019966 | Substance-Related Disorders |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided